Related Experiment Video
Updated: Aug 2, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Automatic border detection identifies subclinical anthracycline cardiotoxicity in children with malignancy
I Hashimoto1, F Ichida, M Miura
1Department of Pediatrics, First Division of Surgery, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan.
Background:
Anthracycline drugs for cancer therapy often cause functional myocardial impairment even in relatively low doses. We investigated the left ventricular function in asymptomatic anthracycline-treated children by automatic border detection (ABD) to assess its clinical usefulness for unmasking latent anthracycline-induced myocardial damage.
Methods And Results:
Thirty-four children (0.7 to 17.6 years old) during or after anthracycline chemotherapy (26 to 1100 mg/m2) for malignancy (Chemo group) were studied, and 40 children (2.8 to 15.6 years old) without cardiac involvement served as normal control subjects (Control group). All patients underwent complete echocardiographic examination, including M-mode, Doppler, and ABD. Conventional echocardiography disclosed no difference between groups with regard to ejection fraction and the ratio of early to late transmitral flow velocity. In marked contrast, an investigation using ABD revealed that the Chemo group appeared to have some anthracycline-induced myocardial damage. In the apical 4-chamber view, peak filling rate in the Chemo group [2.3+/-0.4 end-diastolic area (EDA)/s] was significantly lower than that in the Control group (3.1+/-0.5 EDA/s) (P<0.0001), and time to peak filling rate in the Chemo group (106+/-31 ms) was clearly prolonged compared with that in the Control group (74+/-22 ms) (P<0.0001).
Conclusions:
Echocardiographic ABD may be a sensitive and useful noninvasive approach for evaluating subclinical anthracycline cardiotoxicity.
Insights
Automatic border detection (ABD) can identify subclinical heart damage in children treated with anthracycline chemotherapy, even when standard echocardiography shows normal function. This sensitive method detects early signs of cardiotoxicity.
Area of Science:
- Cardiology
- Pediatric Oncology
- Medical Imaging
Background:
- Anthracycline chemotherapy can cause myocardial impairment in children, even at low doses.
- Early detection of cardiotoxicity is crucial for managing treatment and preventing long-term heart damage.
Purpose of the Study:
- To evaluate the clinical usefulness of automatic border detection (ABD) for identifying latent myocardial damage in asymptomatic children treated with anthracyclines.
- To assess if ABD can unmask subclinical anthracycline-induced cardiotoxicity.
Main Methods:
- Studied 34 children undergoing or having completed anthracycline chemotherapy (Chemo group) and 40 healthy children (Control group).
- All participants underwent comprehensive echocardiography, including M-mode, Doppler, and automatic border detection (ABD).
- Compared left ventricular function parameters between the groups using conventional echocardiography and ABD.
Main Results:
- Conventional echocardiography revealed no significant differences in ejection fraction or transmitral flow velocity between groups.
- Automatic border detection (ABD) showed significantly reduced peak filling rate (P<0.0001) and prolonged time to peak filling rate (P<0.0001) in the Chemo group compared to controls.
- These findings suggest subclinical myocardial damage in children treated with anthracyclines.
Conclusions:
- Echocardiographic ABD is a sensitive and valuable noninvasive tool for assessing subclinical anthracycline cardiotoxicity in children.
- ABD can detect early signs of heart damage missed by conventional echocardiographic methods.
More Related Videos
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022